SCHEMBL3593133

SCHEMBL3593133

Cc1ccc(-c2ccc3ccn(CC(=O)NC(C)(C)CN4CCCC4)c3c2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRIN2B Q13224 4/20 0.43
▸ NPC1 O15118 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ KDM4E B2RXH2 5/20 0.39
▸ HPGD P15428 4/20 0.39
▸ ALDH1A1 P00352 4/20 0.39
▸ HSD17B10 Q99714 4/20 0.39
▸ POLB P06746 3/20 0.39
▸ APOBEC3A P31941 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ APOBEC3G Q9HC16 1/20 0.39
▸ HTR7 P34969 2/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ HDAC4 P56524 1/20 0.39
▸ LMNA P02545 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ RXFP1 Q9HBX9 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3605190 0.81 KMT2A (0.49) GRIN2BNPC1KMT2AKDM4EHPGD
SCHEMBL3597719 0.80 KMT2A (0.48) GRIN2BNPC1KMT2AKDM4EHPGD
SCHEMBL3602569 0.80 KMT2A (0.48) GRIN2BNPC1KMT2AKDM4EHPGD
SCHEMBL3605733 0.80 ALDH1A1 (0.48) GRIN2BNPC1KMT2AKDM4EHPGD
SCHEMBL3598861 0.79 ALDH1A1 (0.47) GRIN2BNPC1KMT2AKDM4EHPGD
SCHEMBL3608528 0.77 MTNR1A (0.47) GRIN2BNPC1KMT2AKDM4EHPGD
SCHEMBL3605111 0.76 KMT2A (0.44) GRIN2BNPC1KMT2AKDM4EHPGD
SCHEMBL3593360 0.74 NTSR1 (0.45) GRIN2BNPC1KMT2AKDM4EHPGD
SCHEMBL3606199 0.74 KMT2A (0.41) GRIN2BNPC1KMT2AKDM4EHPGD
SCHEMBL3595316 0.73 NPC1 (0.44) GRIN2BNPC1KMT2AKDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 — — US disclosed
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 — — US disclosed
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 — — US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 — — US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 — — US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 — — US disclosed
WO-2007115231-A2 CXCR4 MODULATORS CHEMOCENTRYX, INC. (US) 2007-10-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275965-A1 CXCR4 modulators CXCL12, CXCR4, CXCR1 GRIN2B 2950/4885NPC1 334/4885KMT2A 3838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback